The development of the first authentic BH3 mimetic, ABT-737, which heralded the onset of translation of the above findings into new anticancer medicines.
The recent FDA approval of a BH3 mimetic, venetoclax, for CLL, was a cancer breakthrough. What do you see as the main opportunities and challenges for effective translation of these therapies?
The life-death switch controlled by the BCL-2 family operates downstream from oncogenic mutations affecting numerous signaling pathways. Furthermore, cancer cells are more closely poised to apoptose than are normal cells. Hence, BH3 mimetics should be effective for many cancer cell types.
Although venetoclax has shown notable activity as a single agent for CLL, optimal therapy for most tumor types will most likely require supplementation with another anticancer agent, hopefully used at a lower concentration than would be normally be required for that drug.
As with traditional cancer therapeutics, the challenge is how to use BH3 mimetics without causing unacceptable collateral damage. This requires deepening our understanding of the balance of pro-and antiapoptotic proteins within all normal cell types and tumors, so that we can better predict which BH3 mimetic will be the most effective in a particular tumor type, and which normal cell types would be most at risk with the regimen that is most effective for the tumor.
Many tumors express high levels of the BCL-2 prosurvival family member MCL-1, which renders them resistant to both navitoclax (specific for BCL-2, BCL-x L , and BCL-w) and venetoclax (specific for BCL-2). Thus, the recent announcement of MCL-1-specific inhibitors is generating much excitement. These new agents should greatly expand the range of tumors likely to be responsive to BH3 mimetic therapy and clinical trials are eagerly awaited. Although safety concerns have been raised by studies of mcl1 -/-mice showing vulnerability of cardiomyocytes, liver cells, and neurons, a suitable therapeutic window may well be found because mcl1 +/-mice, which should mimic 50% inhibition of the Mcl-1 protein, are normal and healthy. Similar arguments can be made for a Bcl-x L -specific BH3 mimetic, which could prove useful for treating the many solid tumors that express high levels of Bcl-x L , provided safe regimens can be implemented to avoid its toxicity for platelets, which are Bcl-x L dependent.
A current challenge is to determine whether BH3 mimetics can be used safely in combination with various conventional anticancer agents and, looking further ahead, with each other. All in all, the prospects for BH3 mimetic cancer therapy are enormously exciting.
Where can we apply therapeutic manipulation of cell death beyond cancer?
One likely application is in immunosuppression. Gene ablation studies in mice have taught us that apoptosis is vital for shaping the immune repertoire and for shutting down immune responses at the appropriate time. Indeed, a failure of cell death can readily provoke autoimmunity. Thus, BH3 mimetics offer considerable potential as more selective immunomodulatory drugs than conventional agents.
It is thought that apoptosis may have evolved largely to curtail infections by pathogens. To counter this, many pathogens have developed genes that impair apoptosis, such as the BCL2 homologs in certain viruses and parasites. As the pathogen sequences often differ radically from those of the mammalian host, it should be feasible to develop pathogenspecific BH3 mimetics to limit the spread of such infections.
On the other side of the coin, degenerative conditions arise from overly active cell death. Therefore, there is considerable interest in designing small molecules to inhibit the activation of Bax and Bak, with a view to testing their therapeutic potential as agents to prevent certain degenerative diseases.
What is the future of studying cell death and survival and what are the outstanding questions?
Determining how oligomerization of Bax and Bak permeabilizes the outer mitochondrial membrane remains the outstanding scientific question in apoptosis research. Securing the answer has seemed tantalizingly close for several years, but further technological advances in imaging and structural analysis of membrane-bound proteins may yet be required.
On the clinical side, the Holy Grail is to learn how to use BH3 mimetic therapy, either alone or in combination with other drugs, to achieve durable cures, hopefully without the need for ongoing treatment. 
Trends Talk
Mel Greaves: Cancer through the Lens of Evolution 'One general law, leading to the advancement of all organic beings, namely, multiply, vary, let the strongest live and the weakest die' (Charles Darwin in On the Origin of Species). More than a century and a half after Darwin made selection a central biological concept, evolutionary biology is at the vanguard of cancer research. How is the Darwinian framework shedding light on cancer incidence, metastasis, or resistance and recurrence? Among the leaders answering these questions is Mel Greaves, Founding Director of the Centre for Evolution at The Institute of Cancer Research (ICR) in London, UK. His pioneering studies led to some of the most fascinating discoveries on the aetiology of childhood leukaemia. We asked Dr Greaves to give us his view on the implications and benefits of embracing an evolutionary perspective towards cancer biology and therapy.
You have always advocated that cancer should be studied from an evolutionary perspective. Why is that so?
My answer is both pragmatic and philosophical. Cancer, like other complex problems in biomedicine and science generally, is more likely to be tackled successfully if we have a coherent and unifying view of its fundamental nature.
In the 19th century, cancer was widely regarded by surgeons and pathologists as a 'disease of civilization or stress'. Not much of an advance on the ancient Greek view that cancer was a manifestation of a melancholic predisposition. In the 20th century, inspired by Boveri, it was confidently concluded that cancer was 'a genetic disease'. This has now been superseded in the 21st century with the notion of cancer as 'a disease of the genome'.
There is of course an element of truth in those latter descriptions, but in my view they do not cut it. They fall short and lack context. The problem here relates to how scientists of different disciplines handle the notion and meaning of 'cause'. It is not surprising that epidemiologists, cell and molecular biologists, geneticists, and oncologists, at least in the past, saw the issue of cause somewhat differently with respect to questions and answers. An evolutionary perspective fits the bill. It provides a framework or context that can make sense of the details. Dobzhansky surely had it right in 1973 when he opined that 'Nothing in biology makes sense except in the light of evolution.' Although I doubt if he had pathology and medicine in mind as well.
In 1976, Peter Nowell, in his landmark review in Science, highlighted that cancer clones evolve or change over time, and that this has relevance to treatment. Embed that concept within a Darwinian ecosystem context, and empower it with genomic insights, and we have the essence of cancer clone development, as most practitioners of cancer research and oncology now recognise. It's taken a while.
But it is much more than that. I have argued that by focusing on proximate causal factors (important though they may be from the perspective of prevention) we miss a whole dimension of risk. Cancer risk is inherent to the evolutionary 'design' of genome mutability, stem cells, multicellularity, and our prior (beneficial) adaptations; for example with skin pigmentation and hormonal cycles. For me, causal exposures only make sense in that context. And, finally, the resilience of advanced cancer to therapeutic assault is perhaps what you should expect of a semi-autonomous and robust cellular parasite. They can call on survival tactics for which there is a billion-year memory -playing by numbers with rare escapees fuelled by the lottery of random mutation, exploiting signal network plasticity or hunkering down in a dormant state. It's survival of the fittest.
I started my scientific career in the 1960s learning evolutionary biology from John Maynard Smith and others, so I was primed, and may be biased, from that point on. But somehow the answer now just seems so dammed obvious.
How are new technologies enabling evolutionary studies?
There is no substitute for creative ideas in science but, unquestionably, technological innovations greatly fuel and accelerate progress. They are enabling.
Evolutionary studies in cancer to date, especially on cancer clone evolution, have benefited in particular from singlecell analytical methods: monoclonal antibody-based immune-phenotyping, gene expression signatures, genotypes and lineage-tracking in vivo. These tools have revealed remarkably complex and dynamic phylogenetic architectures of cancer cell clones and their variegated genetics.
Tracking clonal evolution in real time via sensitive serial screening of cell-free DNA in plasma now offers the prospect of monitoring the emergence of recurrent or resistant clones, enabling prompt intervention. This circumvents some of the problems linked to the complex topography of subclonal distribution in tissues and the inherent selectivity or bias of biopsies.
Where do you feel cancer evolutionary biology will have the biggest impact?
The only thing that we can reliably predict about the future is that it will happen. I certainly hope that an evolutionary perspective will strongly endorse the importance and potential impact of prevention and early intervention in cancer. The epidemiological evidence linking most common cancers to potentially avoidable or modifiable lifestyle factors is strong. Early tumours in most, although perhaps not all cases, will be less resilient to challenge. A caveat is that we need to be smarter at distinguishing or predicting bad from benign players.
The biggest challenge is how best to thwart the evolutionary resilience of cancers that present late in the clinic, for example those of pancreas, lung, brain, and ovary. Evolutionary principles and methods are likely to be important, and there is much that could be learned or borrowed from other fields -antibiotic resistance in bacteria and drug resistance in malaria, tuberculosis, and HIV. Some promising ideas are currently being explored including therapeutic combinations, coopting the versatility of recognition of the immune system into an arms race in cancer. A new and exciting prospect is evolutionary steering. Studies in simpler microbial systems suggest that it may be possible to design scheduling of drug combinations to steer or push cancer clone evolution into a more benign culde-sac.
What are the most exciting questions in cancer evolution?
Once you embrace an evolutionary perspective, a host of exciting questions are opened up. For me, one of the most interesting is whether it is possible to both predict in advance and then modify cancer clone evolutionary trajectories.
I subscribe to the view that cells with selfrenewal, or stem cell-like potential, are the cellular drivers of cancer evolutionary progression, metastasis, and recurrence or relapse. The necessary caveat is that this is not an inherent or stable state. I am excited by the prospect of learning more about how the self-renewal option operates and is regulated. Personalised, genome-guided therapeutics are a real if challenging prospect, but isn't there an opportunity also for a more generic approach tackling cancer via the essential self-renewal bottleneck?
What other issues or challenges remain unresolved in the drive to understand and exploit the evolutionary biology of cancer?
A whiff here of Rumsfeld's unknown unknowns? We do have some important known unknowns. We still remain ignorant of some of the crucial biology of cancer cells and are probably underestimating complexity. I am somewhat wary of a very gene-centric approach. It would be interesting and potentially of practical value if we had more insight into the ecosystem pressures that select for improved fitness of cancer cells. But then to understand cellular fitness, we also need to have a better grasp of how inherited gene variants and acquired mutations operate collectively or epistatically in a network providing the phenotypic substrates for selection.
Despite being a biologist rather than a clinician, I have always been a strong advocate of 'real' or patient-based studies. Nevertheless, I suspect that further validation and understanding of the ecology of cancer will require better models of the disease in vivo and in more realistic 3D culture systems.
Are there other areas of medicine where evolutionary thinking has or can make a difference?
Certainly, and most obviously with antibiotic resistance, which has recently been highlighted at the UN as an urgent, worldwide problem. Evolutionary or Darwinian medicine is a relatively new branch of biomedical sciences that seeks to apply evolutionary principles to all areas of medicine including chronic diseases of modern societies -diabetes, obesity, and neurodegenerative conditions.
Perhaps the clearest example, other than cancer, of evolutionary ideas being highly pertinent to medicine is with infectious disease. Here we witness, not dissimilarly to cancer, an arms race between rapidlyevolving pathogenic species and the immune surveillance system. Vaccination can tip the balance in our favor, but high mutation rates and fast replication are winning cards for the bugs.
Overall, are you optimistic that evolutionary studies of cancer will be beneficial?
One must be an optimist to survive and thrive in science. But there are real and tangible reasons for being optimistic that an evolutionary perspective on cancer will pay rich dividends; not least it's logical coherence, technological underpinning, and the superb cadre of young scientists now active in the field. 
